Kenvue Sees Unusually Large Options Volume (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) saw unusually large options trading on Monday. Traders bought 83,305 call options on the company. This represents an increase of 116% compared to the average volume of 38,564 call options.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently bought and sold shares of the business. Pittenger & Anderson Inc. bought a new position in Kenvue during the 1st quarter worth approximately $30,000. Trust Co. of Vermont lifted its holdings in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the 1st quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KVUE. Citigroup reduced their price objective on Kenvue from $24.50 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 15th. Royal Bank Of Canada reduced their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research report on Friday, August 8th. Bank of America reduced their price objective on Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, July 15th. Canaccord Genuity Group reduced their price objective on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Evercore ISI reduced their price objective on Kenvue from $25.00 to $23.00 and set an “in-line” rating on the stock in a research report on Monday. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $24.21.

Kenvue Stock Performance

Kenvue stock opened at $18.90 on Wednesday. The stock has a fifty day moving average price of $21.28 and a 200 day moving average price of $22.33. The firm has a market capitalization of $36.27 billion, a P/E ratio of 25.54, a PEG ratio of 2.65 and a beta of 0.83. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $17.15 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the business posted $0.32 EPS. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. Kenvue’s payout ratio is 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.